Q1 FY27 Highlights
- Revenue from operations at Rs. 80,170 mn, up 22% over last year.
- R&D investments for the quarter stood at Rs. 6,424 mn (8% of revenues).
- EBITDA for the quarter was Rs. 19,294 mn, down 8% y-o-y. EBITDA margin for the quarter stood at 24.1%.
- Net Profit for the quarter was Rs. 9,398 mn, down 36% y-o-y.
- Capex (organic) for the quarter was Rs. 5,852 mn.
- Net Debt to Equity ratio as on 30th June 2026 was 0.22x while Net Debt to EBITDA stood at 0.70x at the end of June 2026.
“FY27 is off to a strong, profitable start. We continue advancing into an innovation-led, patient-centric organization. Our branded portfolio now exceeds 55% of revenues. Notably, the share of branded sales in the US reached 11% and will continue to expand with the upcoming Saroglitazar launch. Backed by diverse manufacturing and robust quality systems, we will further strengthen our core businesses and expand our market share. Driven by execution rigor and acquisition synergies, we are well-positioned for our next growth phase.” By Dr. Sharvil Patel, Managing Director – Zydus Lifesciences Limited
India Formulations business
- Registered revenues of Rs. 18,158 mn, up 20% y-o-y. The business accounted for 23% of consolidated revenues.
- The business has consistently outperformed IPM growth over the last 3 financial years.
- Growth during the quarter was broad based as the business grew faster than the market in super-specialty, chronic and acute segments.
- In terms of therapeutic performance, outpaced IPM growth in key therapies of Cardiology, Diabetology, Gynaecology, Anti-infectives, Pain Management and in super specialty areas of Oncology and Nephrology.
- Ranking improved in key therapies of Cardiology, Diabetology and Pain Management while on the super specialty front, retained leadership position in Oncology segment.
North America formulations business
- Registered revenues of Rs. 30,979 mn, down 3% y-o-y and up 5% q-o-q. The business accounted for 40% of consolidated revenues.
- In constant currency terms, the business registered revenues of US$ 327 mn.
- US base business continued to gain market share driven by sustained volume expansion supplemented by new products launches.
- In the US generics space, filed 5 ANDAs, received approval for 9 ANDAs (including 4 tentative approvals) and launched 11 new products during the quarter.
